Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

The role of immunosuppression in lymphoma formation

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Ahuia SS, Shrivastav S, Danielpour D, Balow JE, Boumpas DT (1995) Regulation of transforming growth factor-β1 and its receptor by cyclosporine in human T lymphocytes. Transplantation 60:718

  2. 2.

    Alfrey EJ, Friedman AL, Grossman RA, Perloff LJ, Naji A, Barker CF, Montone KT, Tomajewski JE, Chmielewski C, Holland T, Zmijewski C, Dafoe DC (1992) Two distinct patterns of post-transplantation lymphoproliferative disorder (PTLD): early and late onset. Clin Transplant 6:246

  3. 3.

    Anderson P, Schroeder TJ, Hariharan S, First MR (1993) Incidence of post-transplant lymphoproliferative disease in OKT3-treated renal transplant recipients. Clin Transplant 7: 582

  4. 4.

    Birkeland SA (1983) Cancer in transplanted patients: the Scandia-transplant material. Transplant Proc 15:1071

  5. 5.

    Burner FM (1971) Immunological surveillance in neoplasia. Transplant Rev 7: 3

  6. 6.

    Ciancio G, Siquijor AP, Burke GW, Roth D, Cirocco R, Esquenazi V, Byrne GE Jr, Miller J (1997) Posttransplant lymphoproliferative disease in kidney transplant patients in the new immunosuppressive era. Clin Transplant 11:243

  7. 7.

    Darenkov, IA, Marearelli MA, Basadonna GP, Friedman AL, Lorber KM, Howe JG, Crouch J, Bia MJ, Kliger AS, Lorber, MI (1997) Reduced incidence of Epstein-Barr virus-associated post-transplant lymphoproliferative disorder using preemptive antiviral therapy. Transplantation 64: 848

  8. 8.

    Demetris AJ, Nalesnik MA, Kunz HW, Gill TJ III, Shinozuka H (1984) Sequential analyses of the development of lymphoproliferative disorders in rats receiving cyclosporine. Transplantation 38: 239

  9. 9.

    Doody MM, Linet MS, Glass AG, Friedman GD, Portent LM, Boice JD Jr, Fraumeni IF Jr (1992) Leukemia, lymphoma, and multiple myeloma following selected medical conditions. Cancer Causes Control 3:449

  10. 10.

    Ehrlich P (1957) Über den jetzigen Stand der Karzinomforschung. In: The Collected Papers of Paul Ehrlich vol 2. Pergamon Press, London, p 550

  11. 11.

    Ellis D, Shapiro R, Jordan ML, Scantlebury VP, Gilboa N, Hopp L, Weichler N, Tzakis AG, Simmons RL (1994) Comparison of FK506 and cyclosporine regimens in pediatric renal transplantation. Pediatr Nephrol 8:193

  12. 12.

    Fukuda M, Aikawa I, Ohmori Y, Yoshimura N, Nakai L, Matui S, Oka T (1987) Chromosome aberrations in kidney transplant recipients. Transplant Proc 19: 2245

  13. 13.

    Gershwin ME, Steinberg AD (1973) Loss of suppressor function as a cause of lymphoid malignancy. Lancet 11: 1174

  14. 14.

    Gleichmann E, Gleichmann H, Schwartz RS, Weinblatt A, Armstrong MYK (1975) Immunologic induction of malignant lymphoma: identification of donor and host tumors in the graft-versus-host model. J Natl Cancer Inst 54:107

  15. 15.

    Goldman M, Gerard C, Abramowicz D, Schandené L, Durez P, DePauw L, Kinnaert P, Vereerstraeten P, Velu T (1992) Induction of interleukin-6 and interleukin-10 by the OKT3 monoclonal antibody: possible relevance to post-transplant lymphoproliferative disorders. Clin Transplant 6: 265

  16. 16.

    Goldner H, Girardi AJ, Larson VM, Hilleman MR (1964) Interruption of SV40 virus tumorigenesis using irradiated homologous tumor antigen. Proc Soc Exp Biol 117: 851

  17. 17.

    Gruber SA, Matas AJ (1994) Etiology and pathogenesis of tumors occurring after organ transplantation. Transplant Sci 4: 87

  18. 18.

    Hanto DW, Birkenbach M, Frizzera G, Gajl-Peczalska KJ, Simmons RL, Schubach WH (1989) Confirmation of the heterogeneity of post-transplant Epstein-Barr virus-associated B cell proliferations by immunoglobulin gene rearrangement analyses. Transplantation 47:458

  19. 19.

    Hattori A, Perera MIR, Witkowski LA, Kunz HW, Gill TJ III, Shinozuka H (1986) Accelerated development of spontaneous thymic lymphomas in male AKR mice receiving cyclosporine. Transplantation 41:784

  20. 20.

    Hirsch MS, Proffitt MR, Black PH (1977) Autoimmunity, oncomaviruses, and lymphomagenesis. Contemp Top Immunobiol 6: 209

  21. 21.

    Homef MW, Bein G, Fricke L, Steinhoff J, Wagner H-J, Hinderer W, Sonnebom H-H, Kirchner H (1995) Coincidence of Epstein-Barr virus reactivation, cytomegalovirus infection, and rejection episodes in renal transplant recipients. Transplantation 60: 474

  22. 22.

    Janossy T, Baranyi L, Vizler C, Nyirati I, Végh P (1995) Induction of neonatal transplantation tolerance and lymphoproliferative disorders in mice: the role of F1 donors cells. Transplant Proc 27: 188

  23. 23.

    Kersey JH, Shapiro RS, Heinitz KJ, Greenberg JM, Blazar BR, McClain K, Filipovich AH (1987) Lymphoid malignancy in naturally occurring and post bone marrow transplantation immunodeficiency diseases. In: Good RA, Lindenlaub E (eds) The nature, cellular and biochemical basis and management of immunodeficiencies, vol 21. Shattaeur, Stuttgart, pp 289–294

  24. 24.

    Klein G, Klein E (1977) Immune surveillance against virus-induced tumors and nonrejectability of spontaneous tumors: contrasting consequences of host versus tumor evolution. Proc Natl Acad Sci USA 74:2121

  25. 25.

    Krueger G (1975) The significance of immunosuppression and antigenic stimulation in the development of malignant lymphomas. In Grundmann E, Gross R (eds) The ambivalence of cytostatic therapy, recent results in cancer research, vol 52. Springer, Berlin Heidelberg New York, pp 88–95

  26. 26.

    Lipsky JJ (1996) Mycophenolate mofetil. Lancet 348:1357

  27. 27.

    Lukes RJ, Collins RD (1974) Immunologic characterization of human malignant lymphomas. Cancer 34 [Suppl 4]: 1488

  28. 28.

    Metcalf D (1963) Induction of reticular tumors in mice by repeated antigenic stimulation. Acta Unio Int Contra Cancrum 19: 657

  29. 29.

    Montone KT, Litzky LA, Wurster A, Kaiser L, Bavaria J, Kotloff R, Palevsky H, Pietra GG, Tomaszewski JE (1996) Analysis of Epstein-Barr virus-associated post-transplantation lymphoproliferative disorder after lung transplantation. Surgery 119: 554

  30. 30.

    Nalesnik MA, Starzl TE (1997) On the crossroad between tolerance and post-transplant lymphoma. Curr Opin Organ Transplant 2: 30

  31. 31.

    Nalesnik MA, Locker J, Jaffe R, Reyes J, Cooper M, Fung J, Starzl TE (1992) Experience with posttransplant lymphoproliferative disorders in solid organ transplant recipients. Clin Transplant 6: 249

  32. 32.

    Nalesnik MA, Rao AS, Furukawa H, Pham S, Zeevi A, Fung JJ, Klein G, Gritsch HA, Elder E, Whiteside TL, Starzl TE (1997) Autologous lymphokine-activated killer cell therapy of Epstein-Barr- virus-positive and-negative lymphoproliferative disorders in organ transplant recipients. Transplantation 63: 1200

  33. 33.

    Newell KA, Alonso EM, Whitington, PF, Bruce DS, Millis JM, Piper JB, Woodle ES, Kelly SM, Koeppen H, Hart J, Rubin CM, Thistlethwaite JR Jr (1996) Post-transplant lymphoproliferative disease in pediatric liver transplantation. Interplay between primary Epstein-Barr virus infection and immunosupression. Transplantation 62: 370

  34. 34.

    Penn I (1989) Why do immunosuppressed patients develop cancer? In: Pimentel E (ed) CRC critical reviews in oncogenesis, vol 1.. CRC, Boca Raton, pp 27–52

  35. 35.

    Penn I (1992) Immunosuppression — A contributory factor in lymphoma formation. Clin Transplant 6: 214

  36. 36.

    Penn I (1996) Cancers in cyclosporine-treated versus azathioprine-treated patients. Transplant Proc 28: 876

  37. 37.

    Penn I (1998) Neoplastic complications of organ transplantation. In: Ginns LC, Cosimi AB, Morris PJ (eds) Transplantation. Blackwell, Cambridge (in press)

  38. 38.

    Purtilo DT (1984) Defective immune surveillance in viral carcinogenesis. Lab Invest 51: 373

  39. 39.

    Ras E, Michaeli J, Rosenmann E, Popovtzer M, Polliack A, Shouval D (1993) Excessive hepatitis-B surface antigen production after corticosteroids and the development of immunoblastic lymphoma. Leuk Lymphoma 10: 241

  40. 40.

    Santana V, Rose NR (1983) Immunodysregulation and malignant lymphoproliferative disorders. Rec Adv Clin Immunol 2:51

  41. 41.

    Schwartz RS (1975) Another look at immunologic surveillance. N Engl J Med 293: 181

  42. 42.

    Selik RM, Starcher ET, Curran JW (1987) Opportunistic diseases reported in AIDS patients: frequencies, associations, and trends. AIDS 1: 175–182

  43. 43.

    Sheil AGR, Disney APS, Mathew TG, Amiss N (1993) De novo malignancy emerges as a major cause of morbidity and late failure in renal transplantation. Transplant Proc 25: 1383

  44. 44.

    Starzl TE, Nalesnik MA, Porter KA, Ho M, Iwatsuki S, Griffith BP, Rosenthal JT, Hakala TR, Shaw BW Jr, Hardesty RL (1984) Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporine-steroid therapy. Lancet I: 583

  45. 45.

    Straus SE, Cohen JI, Tosato G, Mier J (1993) Epstein-Barr virus infections: biology, pathogenesis, and management. Ann Intern Med 118: 45

  46. 46.

    Subar M, Neri A, Inghirami G, Knowles DM, Dalla-Favera R (1988) Frequent c-myc oncogene activation and infrequent presence of Epstein-Barr virus genome in AIDS-associated lymphoma. Blood 72: 667

  47. 47.

    Swinnen L, Costanzo-Nordin M, Fisher S, O'Sullivan E, Johnson M, Heroux A, Dizikes G, Pifarre R, Fisher R (1990) Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac transplant recipients. N Engl J Med 323: 1723

  48. 48.

    Thomas L, Medawar PB (1959) Reactions to homologous tissue antigens in relation to hypersensitivity. In Lawrence HS (ed) Cellular and Immoral aspects of the hypersensitive states. Hoeberg, New York, p 529

  49. 49.

    Van Gorp J, Doomewaard H, Verdonck LF, Klöpping C, Vos PF, Tweed JG van den (1994) Posttransplant T-cell lymphoma. Report of three cases and a review of the literature. Cancer 73: 3064

  50. 50.

    Végh P, Baranyi L, Janossy T (1990) Induction of Transplantation tolerance and development of lymphomas in mice: lack of interdependence. Cell Immunol 129:56

  51. 51.

    Walford RL, Hildemann WH (1965) Life span and lymphoma-incidence of mice injected at birth with spleen cells across a weak histocompatibility locus. Am J Pathol 47: 713

  52. 52.

    Wilkinson AH, Smith JL, Hunsicker LG, Tobacman J, Kapelanski DP, Johnson M, Wright FH, Behrendt DM, Corry RJ (1989) Increased frequency of post-transplant lymphomas in patients treated with cyclosporine, azathioprine, and prednisone. Transplantation 47: 293

  53. 53.

    Yuzawa K, Kondo I, Fukao K, Iwasaki Y, Hamaguchi H (1986) Mutagenicity of cyclosporine: induction of sister chromatid exchange in human cells. Transplantation 42: 61

  54. 54.

    Zanke BW, Rush DN, Jeffery JR, Israels LG (1989) HTLV-1 T cell lymphoma in a cyclosporine-treated renal transplant patient. Transplantation 48: 695

Download references

Author information

Correspondence to Israel Penn.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Penn, I. The role of immunosuppression in lymphoma formation. Springer Semin Immunopathol 20, 343–355 (1998). https://doi.org/10.1007/BF00838048

Download citation

Keywords

  • Internal Medicine
  • Lymphoma
  • Lymphoma Formation